Compare DexCom, Inc. (DXCM) vs Lufax Holding Ltd (LU) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

LU trades at $1.33, up 3.1% today, but technical indicators are bearish with moving averages signaling a downtrend. The company reported a net loss of $2.1 billion in 2025, with negative profit margins and returns. Multiple class-action lawsuits filed in May 2026 allege securities fraud, creating significant legal overhangs.

The outlook is challenged by persistent losses and legal risks, though low valuation ratios like P/S of 0.34 and P/B of 0.1 may attract value investors. Analyst consensus is moderately positive with 62% buy ratings, but investors face substantial downside risk from ongoing litigation and profitability concerns.